Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Roberts, Andrew W., Davids, Matthew S., Pagel, John M., Kahl, Brad S., Puvvada, Soham D., Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Brown, Jennifer R., Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B., Cerri, Elisa, Enschede, Sari Heitner, Humerickhouse, Rod A., Wierda, William G., Seymour, John F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/
https://ncbi.nlm.nih.gov/pubmed/26639348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller